Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Multi-center, Randomized, Double-Blind, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of TRA16 Administered Orally in Patients With Enteric Hyperoxaluria (EH).

NCT07871669 is registered in ClinicalTrials.gov with Wuhan Kangfude Urolithiasis Research Institute Co., Ltd. as lead sponsor.

NCT NCT07871669
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07871669 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Multi-center, Randomized, Double-Blind, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of TRA16 Administered Orally in Patients With Enteric Hyperoxaluria (EH).
Lead sponsor
Wuhan Kangfude Urolithiasis Research Institute Co., Ltd.
Phase
Phase 2
Overall status
Not yet recruiting
Start date
March 1, 2027
Completion date
April 2, 2028
Enrollment
30 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

enteric hyperoxaluria